Skip to main content

Related news

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.

Dr. Miquel Vila, head of the Neurodegenerative Diseases research group at VHIR, is the co-chair of the local organising committee. And Dr. Ariadna Laguna, principal investigator of the same group, is a scientific ambassador.

Related professionals

Anna Duarri Piqué

Anna Duarri Piqué

Main researcher
Ophtalmology
Read more
Anna Luque Jiménez

Anna Luque Jiménez

Read more
Laura González Mora

Laura González Mora

Administrative Assistant
Communication Unit
Communication Directorate
Read more
Raquel Bermudo Gascóm

Raquel Bermudo Gascóm

Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.